|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Fair value of loans | ||||||||||||||||||||
| Residential loans, held-for-sale, at fair value | ||||||||||||||||||||
| Residential Consumer Loans Held For Sale | ||||||||||||||||||||
| Residential investor loans, held-for-sale, at fair value | ||||||||||||||||||||
| Residential consumer loans, held-for-investment, at fair value | ||||||||||||||||||||
| Business Purpose Residential Loans, Held-for-Sale | ||||||||||||||||||||
| Residential investor loans, held-for-investment, at fair value | ||||||||||||||||||||
| Consolidated Agency Multifamily Loans | ||||||||||||||||||||
| Residential investor loans | ||||||||||||||||||||
| Home equity investments | ||||||||||||||||||||
| Real estate securities | ||||||||||||||||||||
| Servicing investments | ||||||||||||||||||||
| Strategic investments | ||||||||||||||||||||
| Derivative assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Short-term debt, net | ||||||||||||||||||||
| Asset-backed securities issued | ||||||||||||||||||||
| Debt obligations, net | ||||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Preferred stock, par value $0.01 per share, 2,990,000 shares authorized; 2,800,000 issued and outstanding | ||||||||||||||||||||
| Common stock, par value $0.01 per share, 392,010,000 shares authorized; 125,607,457 and 124,459,837 issued and outstanding | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Cumulative earnings | ||||||||||||||||||||
| Cumulative distributions to stockholders | ||||||||||||||||||||
| Total Equity | ||||||||||||||||||||
| Total Liabilities and Equity |
Loading...
